title: Hydrogen Sulfide-Releasing Therapeutics: Translation to the Clinic.
abstract: Shortly after the discovery of the role of hydrogen sulfide (H2S) in many physiological and pathological processes, attempts were made to develop novel pharmaceuticals that may be of benefit for treatment or prevention of a wide range of disorders. The promise of H2S-based therapeutics is now being demonstrated in clinical trials. Recent Advances: H2S-releasing drugs, such as SG1002 for cardiovascular disorders, and ATB-346 for arthritis, have progressed into clinical trials and have shown considerable promise. Some older drugs, such as zofenopril, have now been recognized to produce at least some of the beneficial effects through release of H2S.
  
  
  
  There remains a need to better understand the underlying mechanisms for some of the observed effects of H2S-releasing drugs in a clinical setting, such as the marked increase in analgesic potency that has been observed with ATB-346.
  
  
  
  The proof-of-concept clinical studies reviewed herein pave the way for examination, in a clinical setting, of several other potential applications of H2S-based drugs in a wide range of disorders, including diabetes, hypertension, and cancer chemoprevention. Antioxid. Redox Signal. 28, 1533-1540.
authors.affiliation: 1 Department of Physiology and Pharmacology, University of Calgary , Calgary, Canada .|2 Antibe Therapeutics, Inc. , Toronto, Canada .|3 Universidade Camilo Castelo Branco , Department of Medicine, Fernandopolis, Brazil .
authors.forename: John L
authors.initials: JL
authors.lastname: Wallace
authors.affiliation: 2 Antibe Therapeutics, Inc. , Toronto, Canada .
authors.forename: David
authors.initials: D
authors.lastname: Vaughan
authors.affiliation: 1 Department of Physiology and Pharmacology, University of Calgary , Calgary, Canada .
authors.forename: Michael
authors.initials: M
authors.lastname: Dicay
authors.affiliation: 1 Department of Physiology and Pharmacology, University of Calgary , Calgary, Canada .
authors.forename: Wallace K
authors.initials: WK
authors.lastname: MacNaughton
authors.affiliation: 3 Universidade Camilo Castelo Branco , Department of Medicine, Fernandopolis, Brazil .
authors.forename: Gilberto
authors.initials: G
authors.lastname: de Nucci
mesh_terms: D000818:Animals; D001168:Arthritis / Q000188:drug therapy*; D002216:Captopril / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006862:Hydrogen Sulfide / Q000378:metabolism / Q000627:therapeutic use*; D009288:Naproxen / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: C550692:2-(6-methoxy-napthalen-2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester; D002317:Cardiovascular Agents; C044958:zofenopril; D009288:Naproxen; D002216:Captopril; D006862:Hydrogen Sulfide
keywords: cardiovascular; chemoprevention; inflammation; nitric oxide; pain; pharmaceuticals